ReviewInternational urology and nephrology2025
Integrating biomarker clustering for improved diagnosis of interstitial cystitis/bladder pain syndrome: a review.
Review in International urology and nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- External validation of combining clinical parameters and urinary biomarker clusters and development of a nomogram for identifying bladder-centric interstitial cystitis/bladder pain syndrome in patients with lower urinary tract symptoms.International urology and nephrology · 2026Article
- Multi-omics analysis identifies a microbiota-bile acid-TLR signaling axis driving bladder injury in interstitial cystitis.Nature communications · 2025Article
- Integrative Diagnostic Model Combining Urinary Biomarkers and Clinical Parameters to Improve Diagnostic Performance in Interstitial Cystitis/Bladder Pain Syndrome.European urology open science · 2025Article
Corrections and comments
- Erratum issued
Authors and funding
2 authors.
Funding
Abstract
Interstitial cystitis/bladder pain syndrome (IC/BPS) is a debilitating chronic condition characterized by pelvic pain and urinary disturbances, making its diagnosis challenging due to overlapping symptoms with various lower urinary tract disorders. Current diagnostic methods primarily rely on subjective evaluations, leading to significant difficulties in accurately identifying and managing IC/BPS. This review explores the potential of clustering different disease biomarkers to enhance diagnostic precision for IC/BPS. We examine current research identifying non-invasive biomarkers, including inflammatory markers, oxidative stress indicators, and neurogenic growth factors, while emphasizing the limitations inherent in single biomarker approaches. By employing cluster analysis, which integrates diverse biomarker data relevant to IC/BPS, current studies indicate that this integration facilitates improved sensitivity and specificity in diagnosis while enabling personalized treatment strategies. Emerging machine learning techniques further enhance this analytical framework, identifying predictive urinary biomarkers that can assist frontline clinicians in making informed diagnostic decisions. This review also highlights the need for standardized protocols in biomarker collection and analysis, advocating for multi-omics integration and longitudinal studies to uncover disease mechanisms and improve clinical practices. Ultimately, utilizing a cluster of disease biomarkers aims to provide objective diagnostic tools, thereby supporting clinicians in delivering timely and effective interventions that can significantly impact patients' quality of life.
Indexed as
Identifiers
40088357What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.